Sonorous NV Announces Leadership Transition

Medical device company appoints new CEO and Chairman of the Board

Mar. 27, 2026 at 12:40pm

Got story updates? Submit your updates here. ›

Sonorous NV, Inc., a medical device company focused on cerebral venous diseases, has announced management changes. Paul Brooke, a current Board member, has become Chairman of the Board. Joel Harris, previously President, has become the new Chief Executive Officer, replacing David Ferrera who has stepped down from the CEO role.

Why it matters

The leadership transition at Sonorous NV comes at an important time as the company advances its flagship BosSTENT product and pipeline. The new CEO and Chairman bring decades of experience in the medical device industry and will provide strategic oversight as Sonorous seeks regulatory approvals and broader market access.

The details

Joel Harris, with over 35 years of experience in the medical device industry, will assume the role of CEO, effective immediately. Paul Brooke has been elected Chairman of the Board, also effective immediately. Brooke brings significant governance and strategic oversight experience. The company maintains strong momentum with its BosSTENT device, having received key regulatory approvals and designations to support future commercialization.

  • On March 27, 2026, Sonorous NV announced the management changes.

The players

Paul Brooke

A current Board member who has become the new Chairman of the Board at Sonorous NV.

Joel Harris

The new Chief Executive Officer of Sonorous NV, replacing David Ferrera. Harris has over 35 years of experience in the medical device industry.

David Ferrera

The former Chief Executive Officer of Sonorous NV who has stepped down from the role.

Sonorous NV, Inc.

A medical device company focused on innovative, physician-inspired technologies for cerebral venous diseases.

Got photos? Submit your photos here. ›

What they’re saying

“I am honored to lead Sonorous at this important time. We remain focused on advancing the BosSTENT™ and transforming outcomes for patients.”

— Joel Harris, Chief Executive Officer

“Sonorous is entering an exciting phase of clinical and regulatory progress. With Joel Harris as CEO and our executive team, we are confident the team will deliver meaningful innovation to patients without distraction.”

— Paul Brooke, Chairman of the Board

What’s next

Sonorous NV is advancing toward IDE submission and broader market approvals for its BosSTENT device.

The takeaway

The leadership transition at Sonorous NV positions the company well to continue its progress in developing innovative medical devices for cerebral venous diseases, with the new CEO and Chairman bringing extensive industry experience to guide the company's strategic direction.